The Frontier
Emerging signals from the onconephrology literature, predicted toxicities for the newest agents, and strategies that might protect the kidney.
Mostly hypothesis-level. Not medical advice. Each observation below carries its own evidence grade: most are under-published, anecdotal, or extrapolated from mechanism and drug class, and a few rest on established data. It captures what experienced clinicians are actively puzzling over — to spur vigilance and study, not to guide treatment.
Emerging signals
Observations from practicing onconephrologists — graded by how much evidence exists, from established through anecdotal discussion.
Beyond the known 'creatinine bump' from blocked tubular secretion, clinicians report genuine AKI with glomerular-range albuminuria — reversible on withdrawal, recurrent on rechallenge — with near-normal light microscopy.
Possible podocytopathy vs true tubular injury; confounded by profuse diarrhea. The rechallenge-positive pattern strongly implicates the drug.
Use cystatin C or measured GFR to separate real injury from a creatinine-secretion artifact before stopping effective therapy.
The same Nectin-4 ADC has produced the full spectrum of AKI across centers — prerenal (diarrhea-driven), acute interstitial nephritis, and acute tubular necrosis.
MMAE payload tubular toxicity plus immune-mediated interstitial injury; steroid response is inconsistent and the drug often must be switched.
Biopsy when feasible — the lesion dictates whether steroids will help.
A newly recognized acute interstitial nephritis pattern in lung-cancer patients, reported by multiple centers concurrently.
EGFR-MET bispecific immune activation in the interstitium — a pattern not yet well captured in the literature.
A myeloma patient on this GPRC5D bispecific developed C3 glomerulonephritis driven by lambda light chains and complement factor H affinity.
Light-chain–complement interaction unmasked during bispecific therapy; expect a lag between hematologic and renal response.
Severe AKI (creatinine 0.7 → 4.8 mg/dL) with uncertain mechanism.
SN-38 (active irinotecan metabolite) diarrhea-mediated prerenal injury vs an intrinsic tubular component — still debated.
Query of thrombotic microangiopathy with this folate-receptor-α ADC.
DM4 maytansinoid endothelial toxicity — analogous to other ADC/chemo TMA.
PLA2R-negative membranous nephropathy with nephrotic-range proteinuria, remitting after switching to imatinib.
Off-target podocyte/immune effect of the BCR-ABL TKI — consider a drug cause for new nephrotic syndrome weeks after starting therapy.
Thrombotic microangiopathy with AKI and pancytopenia in metastatic prostate cancer — alongside an inverse hypothesis that PARP inhibition might ameliorate VEGF-inhibitor endothelial injury.
Endothelial / marrow toxicity; the protective hypothesis is unproven.
Creatinine elevation usually 'pseudo-AKI' from blocked tubular creatinine secretion — but at least one case showed a falling cystatin-C GFR, suggesting true injury.
Inhibition of tubular creatinine transporters mimics AKI; cystatin C / measured GFR distinguishes artifact from real injury.
Don't stop effective therapy for a creatinine rise until you've confirmed real injury.
AKI, thrombotic microangiopathy and hypertension — one of the most-discussed drug-induced TMA signals in myeloma practice.
Proteasome-inhibitor endothelial toxicity, often dose-related and partly reversible.
Profound, sometimes life-threatening hypocalcemia in advanced CKD / dialysis — increasingly used as a zoledronate alternative when renal function precludes bisphosphonates.
RANKL blockade halts bone calcium efflux; not directly nephrotoxic but a major electrolyte hazard in low GFR.
Aggressively replete calcium/vitamin D and monitor closely when GFR is low.
CRS-associated AKI in myeloma plus open questions about proteinuria; dialysis/PD dosing is being worked out empirically (MW ~145 kDa, presumed not dialyzed).
Cytokine release syndrome hemodynamics; the large antibody is not expected to clear on dialysis.
A measurable 'pseudo-decrease' in kidney function — creatinine rises without true GFR loss, with creatinine–cystatin C discordance — risking unnecessary dose reductions.
Inhibition of tubular creatinine secretion (OCT2/MATE), not real injury. Confirm with cystatin C before changing the dose.
Ilyas et al., Kidney Med 2026 (PMID 42179809) quantified the magnitude of this artifact.
Refractory hyperglycemia and diabetic ketoacidosis — a labeled, sometimes fatal metabolic toxicity of this MMAE antibody-drug conjugate — reported with oliguric AKI, separate from the drug's tubular spectrum.
Osmotic diuresis and volume loss from fulminant hyperglycemia drive the AKI; no tubular lesion is established for this pattern. MMAE is cleared via CYP3A4, and one refractory DKA case resolved after pharmacologic CYP3A4 enzyme induction.
Theoretical toxicities, graded by likelihood
Predicted kidney risks for the newest and trial-stage agents, where renal data is thin — each graded Probable, Plausible or Speculative with the reasoning shown.
TROP2 antibody-drug conjugate
Proximal tubular injury / ATN and proteinuria
TROP2 is expressed on tubular epithelium, and the deruxtecan (DXd) payload class already shows tubular signals with trastuzumab deruxtecan and enfortumab vedotin.
Basis: Extrapolated from the ADC class and TROP2 tissue distribution.
HER2 antibody-drug conjugate
Tubular injury and proteinuria
Scattered real-world AKI and proteinuria reports with a shared DXd topoisomerase-I payload; under-published relative to its rapidly expanding use.
Basis: Emerging case reports + ADC class effect.
DLL3×CD3 bispecific (BiTE)
CRS-driven prerenal AKI and tumor lysis
T-cell–engaging bispecifics reliably produce cytokine release syndrome with capillary leak and hemodynamic AKI, as seen across the BiTE/bispecific class.
Basis: Class effect of CD3 bispecifics (blinatumomab, teclistamab).
Menin inhibitor
Differentiation syndrome → capillary leak AKI and tumor lysis
Menin inhibitors induce leukemic differentiation; differentiation syndrome (like ATRA/IDH inhibitors) carries capillary-leak AKI and TLS risk.
Basis: Mechanistic analogy to IDH inhibitors and ATRA.
AKT inhibitor
Prerenal AKI from diarrhea; metabolic disturbance
Prominent diarrhea and hyperglycemia can drive volume depletion and prerenal injury; a direct renal lesion is not established.
Basis: Toxicity profile of the agent; no confirmed intrinsic nephrotoxicity.
HIF-2α inhibitor
Functional creatinine rise; possible true tubular effect
HIF-2α modulation alters erythropoiesis and renal physiology; observed creatinine elevations are hard to separate from co-administered TKIs.
Basis: Real-world observations, mechanism still being characterized.
KRAS G12C inhibitor
Podocyte / glomerular injury beyond the secretion artifact
The adagrasib rechallenge-positive albuminuria signal raises the possibility of a class podocyte effect; sotorasib data are still sparse.
Basis: Analogy to the adagrasib real-world signal.
Antibody-drug conjugates (broad)
Payload-specific tubular toxicity and TMA
As ADC payloads (MMAE, DM4, DXd, calicheamicin) proliferate, off-target endothelial and tubular toxicity is likely to emerge faster than dedicated renal studies.
Basis: Pattern recognition across the expanding ADC landscape.
HER2 exon20 TKI (investigational)
Benign creatinine rise via tubular secretion inhibition
Many HER2/EGFR-family TKIs inhibit tubular creatinine transporters, producing pseudo-AKI without true injury — but trial-stage renal data are absent.
Basis: Speculative extrapolation from related TKIs; no clinical renal data yet.
HIF-2α inhibitor (investigational)
Anemia-related hemodynamics; uncertain direct renal effect
By analogy to belzutifan; the renal safety profile of this trial-stage agent is unknown.
Basis: Speculative class analogy; awaiting trial data.
HSV-1 oncolytic immunotherapy, given intratumorally with nivolumab
Immune-mediated AIN carried by the nivolumab partner, not by the virus
The regimen is always combination immunotherapy, so its renal risk is the checkpoint-inhibitor one the atlas covers in depth; the oncolytic is delivered into the lesion rather than systemically, and its pivotal trial reports no renal signal of its own.
Basis: IGNYTE phase I/II (PMID 40627813): intratumoral dosing alongside nivolumab in 140 patients, with no kidney-specific toxicity named. No SPL posted as of 2026-08.
Renoprotection leads
Strategies that may protect the kidney during nephrotoxic therapy.
SGLT2 inhibitors during cisplatin
Emerging — real-world seriesPreclinical review plus propensity-matched real-world data suggest SGLT2 inhibitors reduce tubular cisplatin uptake and AKI without blunting antitumor efficacy — now in a prospective trial (dapagliflozin + platinum, NCT07018622). Cintrón-García et al., Kidney Int Rep 2026; Mathavan et al., Kidney360 2026.
Magnesium repletion as nephroprotection
Emerging — real-world seriesAnimal models and a multicenter study support magnesium loading to reduce platinum-associated AKI; an RCT is underway. Already recommended to oncologists in parts of onconephrology practice.
Rituximab as a steroid-sparing salvage
Case-level reportsRituximab has enabled control of ICI-associated glomerulonephritis and safe ICI rechallenge in reported cases. Alasadi et al., Clin Kidney J 2025.
Glucarpidase rescue
EstablishedRecombinant carboxypeptidase-G2 cleaves circulating methotrexate, cutting plasma levels ~98.7% within 15 minutes — the definitive antidote for HDMTX-induced AKI with delayed clearance.
2024–2026 & trial-stage agents
The newest frontier and investigational drugs in the catalog. A marker flags agents that are emerging real-world discussion topics where published renal guidance is thinnest.
CRS-driven hypotension → prerenal AKI early in dosing; uveal melanoma.
frontier2024 gastric mAb; severe on-target nausea/vomiting → volume-depletion prerenal AKI.
frontier2025 brain-penetrant oral SERD; renally benign — the only wrinkle is the benign abemaciclib creatinine rise in the combo.
frontier2026 first PROTAC ER degrader; no meaningful intrinsic renal signal.
frontier2022 LAG-3 inhibitor (with nivolumab); class immune-mediated AIN, amplified by combination ICI.
frontier2026 first-in-class CELMoD; no attributable lesion (renal impairment 11% vs 8% on the comparator arm) but exposure rises 1.8x below eGFR 30 off dialysis.
frontier2026 second-gen BCL-2 inhibitor, more potent than venetoclax; tumor-lysis AKI is the class risk, managed with mandated dose ramp-up.
frontier2026 CD123 ADC for BPDCN; renal risk indirect — TLS in the CD123+ disease plus the CD123-class capillary-leak concern; its own dose-limiting toxicity was reversible VOD.
frontier2026 GR antagonist (ovarian); hypokalemia via cortisol/mineralocorticoid receptor — the mifepristone effect, blunted by GR-selectivity.
frontierEGFR-mediated electrolyte (magnesium) wasting; an emerging acute interstitial nephritis signal is also clinician-flagged.
frontier2024 NRG1-fusion bispecific; mostly grade 1-2 AEs — at most diarrhea-related prerenal risk, no CRS/TLS mechanism.
frontier2025 TROP2 ADC; renal signal theoretical, extrapolated from the ADC class.
frontier2024 small-cell lung BiTE; CRS-driven AKI risk.
frontier2024 leukemia agent; differentiation syndrome and tumor lysis.
frontier2024 EGFR TKI; hyponatremia like osimertinib.
frontier2024 biliary-tract HER2 bispecific; renal data emerging.
frontier2024 cellular therapy; high-dose IL-2 conditioning → capillary leak AKI.
frontier2024 pediatric glioma RAF inhibitor; creatinine rise.
frontier2024 MDS agent; tumor lysis risk.
frontier2025 NF1 MEK inhibitor; creatinine rise and edema.
frontier2025 EGFR exon20 TKI; renal magnesium wasting (SIADH-pattern hyponatremia possible).
frontier2025 NPM1-mutated AML menin inhibitor; differentiation syndrome and tumor lysis.
frontierTrial-stage RCC HIF-2α inhibitor; renal profile being defined.
investigationalHER2 exon20 TKI (2025); creatinine rise likely a secretion artifact.
frontier2025 reversible HER2/EGFR TKI; profuse diarrhea (84-91%) → prerenal AKI, plus EGFR-pathway renal magnesium wasting.
frontier2025 imipridone for H3 K27M glioma; renally well tolerated — QT prolongation, not nephrotoxicity, is the safety focus.
frontierPSMA-targeted radioligand for prostate cancer; renal radiation exposure and xerostomia.
frontierCapillary-leak syndrome → prerenal AKI.
frontierCRS-driven AKI and tumor lysis in myeloma.
frontierCRS-driven AKI; delayed neurotoxicity.
frontier2026 IV pan-PI3K + mTORC1/2 (breast); on-target hyperglycemia and low-grade Na/K/Mg drift — creatinine up 14% vs 8% control, grade 3-4 rare.
frontierDifferentiation syndrome and tumor lysis in AML.
frontierTwo nephrotoxic pathways in one molecule: VEGF-blockade glomerular injury plus checkpoint-inhibitor interstitial nephritis.
frontierT-cell redirection, not tubular poison — AKI rides on cytokine release, not the drug itself.
frontierNext-gen ROS1 TKI; benign transporter-mediated creatinine rise (pseudo-AKI), not true GFR loss.
frontier2026 TRK-sparing ROS1 TKI; no creatinine abnormality reached the label's >=20% lab-table cutoff — unlike the class's benign pseudo-AKI rise. Renally quiet so far.
frontierALK TKI carrying the crizotinib-class renal signature: benign creatinine rise and possible renal cysts.
frontierPI3Kα inhibitor whose renal-relevant toxicity is on-target hyperglycemia and electrolyte shifts, not a kidney lesion.
frontierc-Met MMAE antibody-drug conjugate; proximal tubular ATN risk extrapolated from the ADC/MMAE class.
frontierFirst TCR-T cell therapy for a solid tumor; CRS-associated hemodynamic AKI.
frontierCD19 CAR-T for adult B-ALL; CRS- and tumor-lysis-associated AKI, with notably lower high-grade CRS.
frontierJAK2/ACVR1 inhibitor; diarrhea-driven prerenal AKI and electrolyte loss.
frontierRAF/MEK clamp; CK elevation/rhabdomyolysis and tubular electrolyte wasting.
frontierCD20×CD3 bispecific; tumor-lysis urate crystal nephropathy with CRS.
frontier